CLSA Inspire QuickFire Challenge for Diverse Innovators Kicks Off
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, AbbVie and 5AM Ventures, together with Johnson & Johnson Innovation, is proud to launch the CLSA Inspire QuickFire Challenge for Diverse Innovators, the first challenge in the CLSA Inspire series.
CLSA Requests Support for Legislation to Restore R&D Tax Credit to Assist with the State’s Economic Recovery
The California Life Sciences Association (CLSA) sponsored and introduced Assembly Bill (AB) 593, with Assemblymember Cottie Petrie-Norris (AD 74) which reinstates the Research and Development (R&D) Tax Credit and Net Operating Loss (NOL) deductions for life sciences companies in California for tax years 2021 and 2022.
New Data Show Foreign Reference Drug Pricing Proposals Would Reduce the Development of New Innovative Medicines in California by 88%
Release of data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.
Biotech takes on racial and social equity. Are the efforts sustainable?
From holding Covid-19 vaccination events in San Francisco’s Tenderloin neighborhood to building programs that target longstanding inequities, the Bay Area biotech industry is stepping into high-profile social issues like never before.
CLSA/CLSI Announce Initiation of Mentoring, Coaching and Professional Development Programs to Help Address Gaps in Representation and Inequity in the California Life Sciences Industry
Launch of CLSA/CLSI’s new Racial & Social Equity Initiative aims to address inequities faced by Black, Hispanic, Native American and Pacific Islander populations.
CLSA Welcomes New Board Members and Kicks off Robust 2021
Senior level additions to leadership team demonstrate commitment to improved offerings and member experience.
CLSA Applauds the Release the Medicare Coverage of Innovative Technology (MCIT) Final Rule
Earlier this month, the Centers for Medicare and Medicaid Services (CMS) released the final “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary” rule (42 CFR Part 405).
CLSA and BIO hosted a briefing “The Transformative Potential of Gene Therapies”
This November, voters will have the opportunity to vote yes on Proposition 14 to authorize $5.5 billion in state general obligation bonds to continue the advancement of treatments and cures here in
California.
California Unveils New Approach to Vaccine Allocation and Distribution
On Tuesday, January 26, Governor Newsom revised the vaccine rollout plan to help streamline allocation and distribution.
CLSA Joins National Trade Partner BIO in Legal Action Challenging Most Favored Nation Interim Final Rule
CLSA issued a statement after the issuance of the Most Favored Nation (MFN) Interim Final Rule, and our subsequent legal action we have joined with our partners BIO and Biocom.